0001104659-22-004497.txt : 20220114 0001104659-22-004497.hdr.sgml : 20220114 20220114172149 ACCESSION NUMBER: 0001104659-22-004497 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220112 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220114 DATE AS OF CHANGE: 20220114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VYNE Therapeutics Inc. CENTRAL INDEX KEY: 0001566044 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453757789 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38356 FILM NUMBER: 22532742 BUSINESS ADDRESS: STREET 1: 520 U.S. HIGHWAY 22, SUITE 204 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 800-775-7936 MAIL ADDRESS: STREET 1: 520 U.S. HIGHWAY 22, SUITE 204 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Menlo Therapeutics Inc. DATE OF NAME CHANGE: 20180201 FORMER COMPANY: FORMER CONFORMED NAME: Menlo Therapeutics, Inc. DATE OF NAME CHANGE: 20170728 FORMER COMPANY: FORMER CONFORMED NAME: Tigercat Pharma, Inc. DATE OF NAME CHANGE: 20130104 8-K/A 1 tm222963d1_8ka.htm FORM 8-K/A
0001566044 true 0001566044 2022-01-12 2022-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K/A

 

(Amendment No. 1) 

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) January 12, 2022

 

 

 

VYNE Therapeutics Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38356   45-3757789

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification Number)

 

520 U.S. Highway 22, Suite 204

Bridgewater, New Jersey 08807

(Address of principal executive offices, including Zip Code)

 

(800) 775-7936

(Registrant’s telephone number, including area code)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		  

Name of each exchange

on which registered

Common Stock, $0.0001 par value   VYNE   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

 

Explanatory Note

 

On January 12, 2022, VYNE Therapeutics Inc. (“VYNE” or the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Journey Medical Corporation (“Journey”) pursuant to which VYNE divested its Molecule Stabilizing Technology franchise, including AMZEEQ, ZILXI, and FCD105, to Journey (the “Sale”).

 

This Current Report on Form 8-K/A supplements Item 9.01 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2022 related to the completion of the Sale (the "Original Form 8-K"). The purpose of this amendment is to provide certain pro forma financial information in connection with the Sale, and provide additional information with respect to the Company's board of directors (the "Board").

 

Except as set forth herein, no modifications have been made to the information contained in the Original Form 8-K.

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

The Company deeply regrets to announce that Mr. Rex Bright passed away on January 11, 2022. Mr. Bright was a director of the Company and also served as the Chair of the Company’s Compensation Committee and a member of the Company’s Audit Committee.

 

David Domzalski, Chief Executive Officer and Board member, said “on behalf of the Company, its entire board of directors and management team, I would like to acknowledge Rex’s tireless dedication and service to the Company. Rex was an outstanding director and he will be missed not only as a colleague, but also as a friend. We are thankful for his guidance, wisdom and outstanding leadership. We extend our sincerest condolences to Rex’s family.”

 

On January 14, 2022, the Board appointed (i) Patrick LePore to serve as a member of the Company’s Audit Committee and (ii) Elisabeth Sandoval to serve as chairperson of the Compensation Committee.

 

Item 9.01. Financial Statements and Exhibits.

 

(b)   Pro Forma Financial Information

 

The Company’s unaudited pro forma condensed consolidated financial information is included as Exhibit 99.1 hereto and is incorporated by reference in this Item 9.01(b).

 

(d) Exhibits

 

The following exhibit is being filed herewith. 

 

Exhibit No. Description
   
99.1 Unaudited Pro Forma Condensed Consolidated Financial Information.
   
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  VYNE THERAPEUTICS INC.
     
Date: January 14, 2022 By: /s/ Mutya Harsch
   

Mutya Harsch

Chief Legal Officer and General Counsel

 

 

 

 EX-99.1 2 tm222963d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

Unaudited Pro Forma Condensed Consolidated Financial Information

 

Overview

 

On January 12, 2022 (the “Effective Date”), VYNE Therapeutics Inc. (the “Company” or “VYNE”) entered into an Asset Purchase Agreement (the “Agreement”) with Journey Medical Corporation (“Journey” or “Buyer”) pursuant to which the Company sold its Molecule Stabilizing Technology (MSTTM) franchise, including AMZEEQ®, ZILXI®, and FCD105 (the “MST Franchise”), to Journey. The assets include certain contracts, including the license agreement with Cutia Therapeutics (HK) Limited (“Cutia”), inventory and intellectual property related to the MST Franchise (together, the “Assets”). Pursuant to the Agreement, the Buyer assumed certain liabilities of the MST Franchise including, among others, those arising from VYNE’s patent infringement suit initiated against Padagis Israel Pharmaceuticals Ltd. There were no current or long-term liabilities recorded by the Company which were transferred to the Buyer. The sale was consummated concurrently with the execution of the Purchase Agreement.

 

The following unaudited pro forma condensed consolidated financial statements are intended to show how the transaction might have affected the historical financial statements of VYNE if the transaction had been completed at an earlier time as indicated therein. The unaudited pro forma condensed consolidated financial statements have been prepared in accordance with Article 11 of Regulation S-X, and were derived from the Company’s historical consolidated financial statements and are being presented to give effect to the sale of the Assets, presented on a discontinued operations basis in accordance with ASC 205, Discontinued Operations. The unaudited pro forma condensed consolidated financial statements should be read in conjunction with:

 

i.The accompanying notes to the unaudited pro forma condensed consolidated financial statements;
ii.The audited consolidated financial statements of the Company and its subsidiaries and the accompanying notes included in the Company’s Current Report on Form 8-K filed with the SEC on August 12, 2021; and
iii.The unaudited interim historical financial statements of the Company and its subsidiaries, the accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Quarterly Report on Form 10-Q for the nine months ended September 30, 2021 filed with the SEC on November 10, 2021.

 

The unaudited pro forma condensed consolidated financial statements of the Company are based on available information and assumptions that the Company’s management believes are reasonable as of the date of this filing. The unaudited pro forma condensed consolidated statements of operations for the years ended December 31, 2020, 2019 and 2018, and the nine months ended September 30, 2021 present the Company’s results as if the transaction had occurred on January 1, 2018, the beginning of the earliest period presented. The unaudited pro forma condensed consolidated balance sheet as of September 30, 2021 reflects the Company’s assets, liabilities, and equity as if the transaction had occurred on September 30, 2021.

 

The unaudited pro forma condensed consolidated financial statements do not purport to represent the Company’s actual consolidated results of operations or financial condition had the transaction occurred on the dates assumed, nor are they indicative of the Company’s future consolidated results of operations or financial condition.

 

The unaudited pro forma condensed consolidated financial statements have been prepared in accordance with Article 11 of Regulation S-X. Article 11 of Regulation S-X requires that pro forma financial information include the following pro forma adjustments to the historical financial statements of the registrant as follows:

 

  · Transaction Accounting Adjustments – Adjustments that reflect only the application of required accounting to the acquisition, disposition, or other transaction.
     
  · Autonomous Entity Adjustments – Adjustments that are necessary to reflect the operations and financial position of the registrant as an autonomous entity when the registrant was previously part of another entity. There are no autonomous entity adjustments included in the pro forma financial information because VYNE currently operates, and after the completion of the transaction will continue to operate, as an independent, standalone entity.

 

In addition, Regulation S-X permits registrants to reflect adjustments that depict synergies and dis-synergies of the acquisitions and dispositions for which pro forma effect is being given in our disclosures as management adjustments. The unaudited pro forma condensed consolidated financial statements do not include management adjustments to reflect any potential synergies that may be achievable, or dis-synergy costs that may occur, in connection with the sale of the Assets. We have determined not to reflect such adjustments because we do not believe to present such adjustments would enhance an understanding of the pro forma effects of the transaction.

 

 

 

 

The transaction accounting adjustments to reflect the sale of the Assets in the unaudited pro forma condensed consolidated financial statements include:

 

  · The sale of the Assets of the MST Franchise pursuant to the Agreement and the elimination of operating results related to the MST Franchise presented on a discontinued operations basis in accordance with ASC 205, Discontinued Operations.

 

  · The estimated impact of proceeds received in connection with the transaction, net of transaction costs and income taxes paid, and the estimated gain or loss on the sale of the Assets of the MST Franchise.

 

The unaudited pro forma condensed consolidated financial statements are presented for informational purposes only and are based upon estimates by VYNE’s management, which are based upon available information and certain assumptions that VYNE’s management believes are reasonable as of the date of this filing. The unaudited pro forma condensed consolidated financial statements are not intended to be indicative of the actual financial position or results of operations that would have been achieved had the transaction been consummated as of the periods indicated above, nor does it purport to indicate results which may be attained in the future. Actual amounts could differ materially from these estimates.

 

 

 

 

VYNE THERAPEUTICS INC.

Pro Forma Condensed Consolidated Balance Sheet

As of September 30, 2021

(in thousands)

(Unaudited)

 

       Transaction Accounting Adjustments     
  

Historical
VYNE

(a)

  

Discontinued Operations

(b)

   Additional Adjustments
(c)		   Notes   Pro
Forma		 
Assets                        
Current Assets:                        
Cash and cash equivalents  $52,306   $—   $15,570   i   $67,876 
Restricted cash   605    —    —        605 
Trade receivables, net of allowances   10,084    —    —        10,084 
Prepaid and other assets   5,064    (739)   5,000   i    9,325 
Inventory   8,070    (8,070)   —        — 
Total Current Assets   76,129    (8,809)   20,570        87,890 
Property and equipment, net   472    —    —        472 
Operating lease right-of-use assets   1,036    —    —        1,036 
Prepaid and other assets   3,678    —    —        3,678 
Total Assets  $81,315   $(8,809)  $20,570       $93,076 

 

See accompanying notes to unaudited pro forma condensed consolidated financial statements.

 

 

 

 

VYNE THERAPEUTICS INC.

Pro Forma Condensed Consolidated Balance Sheet

As of September 30, 2021

(in thousands)

(Unaudited)

 

       Transaction Accounting Adjustments     
  

Historical
VYNE

(a)

   Discontinued Operations
(b)		   Additional Adjustments
(c)		   Notes   Pro
Forma		 
Liabilities and shareholders’ equity                        
Current Liabilities:                        
Trade payables  $7,621   $—   $—       $7,621 
Accrued expenses   9,613    —    —        9,613 
Employee related obligations   3,382    —    —        3,382 
Operating lease liabilities   277    —    —        277 
Other   104    —    —        104 
Total Current Liabilities   20,997    —    —        20,997 
Liability for employee severance benefits   206    —    —        206 
Operating lease liabilities   775    —    —        775 
Other liabilities   451    —    —       451 
Total Liabilities   22,429    —    —        22,429 
Shareholders' Equity:                        
Preferred stock: $0.0001 par value; 20,000,000 shares authorized at September 30, 2021; no shares issued and outstanding at September 30, 2021   —    —    —        — 
Common stock: $0.0001 par value; 150,000,000 shares at September 30, 2021; 53,510,599 shares issued and outstanding at September 30, 2021   5    —    —       5 
Additional paid-in capital   686,836    —    —        686,836 
Accumulated deficit   (627,955)   (8,809)   20,570        (616,194)
Total Shareholders' Equity   58,886    (8,809)   20,570        70,647 
Total Liabilities and Shareholders’ Equity  $81,315   $(8,809)  $20,570        $93,076  

 

See accompanying notes to unaudited pro forma condensed consolidated financial statements.

 

 

 

 

VYNE THERAPEUTICS INC.

Pro Forma Condensed Consolidated Statement of Operations

For the nine months ended September 30, 2021

(in thousands, except per share data)

(Unaudited)

 

          Transaction Accounting Adjustments        
    Historical VYNE
  (a)		     Discontinued
Operations
  (b)		     Additional
Adjustments
(c)		     Notes     Pro
Forma		  
Revenues                                      
Product sales, net   $ 11,805     $ (11,805 )   $ —           $ —  
Royalty revenues     658       —       —             658  
Total Revenues     12,463       (11,805 )     —             658  
                                       
Cost of goods sold     2,445       (2,445 )     —             —  
                                       
Operating Expenses:                                      
Research and development     19,723       (4,512 )     —             15,211  
Selling, general and administrative     46,283       (29,527 )     —             16,756  
Total Operating Expenses     66,006       (34,039 )     —             31,967  
Operating Loss     55,988       (24,679 )     —             31,309  
Interest Expense     5,610       —       —             5,610  
Other Income, net     161       —       —             161  
Loss Before Income Tax     61,759       (24,679 )     —             37,080  
Income Tax (Benefit) Expense     —       —       —             —  
Net Loss     61,759     $ (24,679 )   $ —           $ 37,080  
Loss per share basic and diluted   $ 1.22                           $ 0.73  
                                       
Weighted average shares outstanding - basic and diluted     50,776                             50,776  

 

See accompanying notes to unaudited pro forma condensed consolidated financial statements.

 

 

 

  

VYNE THERAPEUTICS INC.

Pro Forma Condensed Consolidated Statement of Operations

For the year ended December 31, 2020

(thousands, except per share data)

(Unaudited)

 

       Transaction Accounting Adjustments     
  

Historical VYNE

(a)

   Discontinued
Operations
(b)		   Additional
Adjustments
(c)		   Notes   Pro
Forma		 
Revenues                      
Product sales, net  $10,202   $(10,202)  $—       $— 
License revenues   10,000    (10,000)   —        — 
Royalty revenues   791    —    —        791 
Total Revenues   20,993    (20,202)   —        791 
                         
Cost of goods sold   1,392    (1,392)   —        — 
                         
Operating Expenses:                        
Research and development   43,533    (10,272)   —        33,261 
Selling, general and administrative   89,543    (42,485)   —        47,058 
Goodwill and in-process research & development impairments   54,345    —    —        54,345 
Contingent Stock Remeasurement   84,726    —    —        84,726 
Total Operating Expenses   272,147    (52,757)   —        219,390 
Operating Loss   252,546    (33,947)   —        218,599 
Interest Expense   4,390    —    —        4,390 
Other Income, net   (1,110)   —    —        (1,110)
Loss Before Income Tax   255,826    (33,947)   —        221,879 
Income Tax (Benefit) Expense   (258)   —    —        (258)
Net Loss  $255,568   $(33,947)  $—       $221,621 
Loss per share basic and diluted  $7.88                 $6.84 
                         
Weighted average shares outstanding - basic and diluted   32,418                  32,418 

 

See accompanying notes to unaudited pro forma condensed consolidated financial statements.

 

 

 

 

VYNE THERAPEUTICS INC.

Pro Forma Condensed Consolidated Statement of Operations

For the year ended December 31, 2019

(thousands, except per share data)

(Unaudited)

 

       Transaction Accounting Adjustments     
  

Historical
VYNE

(a)

   Discontinued
Operations
(b)		  

Additional

Adjustments

(c)

   Notes   Pro
Forma		 
Revenues                        
Royalty revenues  $443    —    —       $443 
Total Revenues   443    —    —        443 
                         
Operating Expenses:                        
Research and development   51,202    (36,421)   —        14,781 
Selling, general and administrative   45,114    (23,926)   —        21,188 
Total Operating Expenses   96,316    (60,347)   —        35,969 
Operating Loss   95,873    (60,347)   —        35,526 
Interest Expense   921    —    —        921 
Other Income, net   (1,440)   —    —        (1,440)
Loss Before Income Tax   95,354    (60,347)   —        35,007 
Income Tax (Benefit) Expense   (176)   —    —        (176)
Net Loss  $95,178   $(60,347)  $—       $34,831 
Loss per share basic and diluted  $11.22                 $4.11 
                         
Weighted average shares outstanding - basic and diluted   8,485                  8,485 

 

See accompanying notes to unaudited pro forma condensed consolidated financial statements.

 

 

 

VYNE THERAPEUTICS INC.

Pro Forma Condensed Consolidated Statement of Operations

For the year ended December 31, 2018

(thousands, except per share data)

(Unaudited)

 

       Transaction Accounting Adjustments     
  

Historical

VYNE

(a)

  

Discontinued

Operations
(b)

   Additional
Adjustments
(c)		   Notes   Pro
Forma		 
Revenues                        
Royalty revenues  $3,533    —    —       $3,533 
Other revenues   62    —    —        62 
Total Revenues   3,595    —    —        3,595 
                         
Operating Expenses:                        
Research and development   64,474    (53,090)   —        11,384 
Selling, general and administrative   14,013    —    —        14,013 
Total Operating Expenses   78,487    (53,090)   —        25,397 
Operating Loss   74,892    (53,090)   —        21,802 
Other Income, net   (941)   —    —        (941)
Loss Before Income Tax   73,951    (53,090)   —        20,861 
Income Tax (Benefit) Expense   212    —    —        212 
Net Loss  $74,163   $(53,090)  $—       $21,073 
Loss per share basic and diluted  $11.47                 $3.26 
                         
Weighted average shares outstanding - basic and diluted   6,466                  6,466 

 

See accompanying notes to unaudited pro forma condensed consolidated financial statements.

 

 

 

Notes to the Unaudited Pro Forma Condensed Consolidated Financial Statements

 

On January 12, 2022 the “Effective Date”), VYNE Therapeutics Inc. (the “Company” or “VYNE”) entered into an Asset Purchase Agreement (the “Agreement”) with Journey Medical Corporation (”Journey” or “Buyer”) pursuant to which the Company sold its Molecule Stabilizing Technology (MSTTM) franchise, including AMZEEQ®, ZILXI®, and FCD105 (the “MST Franchise”), to Journey. The assets include certain contracts, including the license agreement with Cutia Therapeutics (HK) Limited (“Cutia”), inventory and intellectual property related to the MST Franchise (together, the “Assets”). Pursuant to the Agreement, the Buyer assumed certain liabilities of the MST Franchise including, among others, those arising from VYNE’s patent infringement suit initiated against Padagis Israel Pharmaceuticals Ltd. There were no current or long-term liabilities recorded by the Company which were transferred to the Buyer. The sale was consummated concurrently with the execution of the Purchase Agreement.

 

The Agreement provides that the consideration payable by the Buyer to the Company for the Assets sold and transferred will consist of the following amounts: (i) a payment of $20.0 million on the Effective Date; (ii) a payment of $5.0 million on the one (1)-year anniversary of the Effective Date; and (iii) milestone payments of up to $450.0 million in the aggregate upon the achievement of specified levels of net sales of the products covered by the Agreement. In addition, Journey has agreed to pay VYNE 10% of any upfront payment received by Journey from a licensee or sublicensee in any territory outside of the United States, subject to specified exceptions.

 

The unaudited pro forma condensed consolidated financial statements reflect the following:

 

a)The Company’s condensed consolidated balance sheet as of September 30, 2021 and consolidated statements of operations for the years ended December 31, 2020, 2019 and 2018 and for the nine months ended September 30, 2021.

 

b)The sale of the Assets pursuant to the Agreement are presented on a discontinued operations basis in accordance with ASC 205-20, Presentation of Financial Statements – Discontinued Operations. Specific adjustments related to this presentation include the following:

 

i.Adjustments to reflect discontinued operations of the assets and liabilities of the MST Franchise consistent with the guidance for discontinued operations under US GAAP. The Company’s current estimates on the discontinued operations basis are preliminary and could change as the Company finalizes the accounting for the discontinued operations to be reported in its Quarterly Report on Form 10-Q for the quarter ending March 31, 2022.

 

ii.The tax impacts have been estimated using the applicable statutory income tax rates in the respective jurisdictions. The estimated income tax adjustments are subject to change and actual amounts may differ from the results reflected herein.

 

c)The estimated cash proceeds received, and deferred cash payments net of transaction costs and taxes related to the gain on the transaction.

 

i.To record the estimated net cash proceeds from the transaction of $20 million paid upon closing and $5 million to be paid upon the one-year anniversary of the Effective Date, less estimated transaction costs of $4.4 million. The Company does not expect to pay any federal or state income taxes based upon utilization of net operating losses. The expected tax effects are calculated based on the amount of taxable gain considering the use of historical net operating losses in place to reduce taxable income, using the applicable statutory income tax rates in the respective jurisdictions, except in jurisdictions for where there was a valuation allowance in place, which resulted in the use of a 0% tax rate. The estimates, including the jurisdictional income tax effects, are subject to change and actual amounts may differ from the results reflected herein. As described above the pro forma statements of operations present the Company’s results as if the transaction had occurred on January 1, 2018. The estimated gain of $11.8 million related to the discontinued operations and the sale has been excluded from the pro forma condensed consolidated statement of operations for the year ended December 31, 2018 as this amount pertains to discontinued operations and does not reflect the impact on income from continuing operations. No proceeds from product payments were included in the pro forma financial statements as they are contingent upon certain milestones and will be accounted for upon the achievement of such milestones.

 

In addition, on the Effective Date, the parties entered into a Transition Services Agreement (“TSA”) for the Company to continue to perform certain operational and administrative services related to the Assets over specified periods of time (up to 6 months in certain instances with the ability of the parties to mutually agree on an extension period). The TSA details the services to be provided, the term over which the services will be provided, and the compensation to be paid by the Buyer to the Company for providing those services. The unaudited pro forma condensed consolidated financial statements do not include any compensation related to the TSA as the agreement is not finalized and compensation related to the TSA cannot be reasonably estimated.

 

 

 EX-101.SCH 3 vyne-20220112.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 vyne-20220112_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 vyne-20220112_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Jan. 12, 2022
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description This Current Report on Form 8-K/A supplements Item 9.01 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2022 related to the completion of the Sale (the "Original Form 8-K"). The purpose of this amendment is to provide certain pro forma financial information in connection with the Sale, and provide additional information with respect to the Company's board of directors (the "Board").
Document Period End Date Jan. 12, 2022
Entity File Number 001-38356
Entity Registrant Name VYNE Therapeutics Inc.
Entity Central Index Key 0001566044
Entity Tax Identification Number 45-3757789
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 520 U.S. Highway 22
Entity Address, Address Line Two Suite 204
Entity Address, City or Town Bridgewater
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08807
City Area Code 800
Local Phone Number 775-7936
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol VYNE
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
XML 7 tm222963d1_8ka_htm.xml IDEA: XBRL DOCUMENT 0001566044 2022-01-12 2022-01-12 iso4217:USD shares iso4217:USD shares 0001566044 true 8-K/A 2022-01-12 VYNE Therapeutics Inc. DE 001-38356 45-3757789 520 U.S. Highway 22 Suite 204 Bridgewater NJ 08807 800 775-7936 false false false false Common Stock, $0.0001 par value VYNE NASDAQ true true This Current Report on Form 8-K/A supplements Item 9.01 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2022 related to the completion of the Sale (the "Original Form 8-K"). The purpose of this amendment is to provide certain pro forma financial information in connection with the Sale, and provide additional information with respect to the Company's board of directors (the "Board"). EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

*+E2J MQ"(6,P$ "(" / " 6@1 !X;"]W;W)K8F]O:RYX;6Q0 M2P$"% ,4 " "WBBY4)!Z;HJT #X 0 &@ @ '($@ M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "WBBY499!Y MDAD! #/ P $P @ &M$P 6T-O;G1E;G1?5'EP97-=+GAM 7;%!+!08 "0 ) #X" #W% ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 122 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://menlotherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm222963d1_8ka.htm tm222963d1_ex99-1.htm vyne-20220112.xsd vyne-20220112_lab.xml vyne-20220112_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm222963d1_8ka.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm222963d1_8ka.htm" ] }, "labelLink": { "local": [ "vyne-20220112_lab.xml" ] }, "presentationLink": { "local": [ "vyne-20220112_pre.xml" ] }, "schema": { "local": [ "vyne-20220112.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "vyne", "nsuri": "http://menlotherapeutics.com/20220112", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm222963d1_8ka.htm", "contextRef": "From2022-01-12to2022-01-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://menlotherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm222963d1_8ka.htm", "contextRef": "From2022-01-12to2022-01-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001104659-22-004497-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-004497-xbrl.zip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end